Professor Anthony Moorman
Professor of Genetic Epidemiology

  • Email: anthony.moorman@ncl.ac.uk
  • Telephone: +44 (0) 191 282 1323
  • Fax: +44 (0) 191 282 1326
  • Address: Leukaemia Research Cytogenetics Group,
    Northern Institute for Cancer Research,
    Newcastle University
    Level 5, Sir James Spence Institute,
    Royal Victoria Infirmary,
    Queen Victoria Road,
    Newcastle upon Tyne
    NE1 4LP

Roles and Responsibilities

Deputy Director of the Leukaemia Research Cytogenetics Group

Qualifications

·         PhD Epidemiology, LRF Centre for Clinical Epidemiology, University of Leeds, 2001

·         MSc Computing Science, Dept. of Computer Science, Birkbeck College, University of London, 1996

·         BSc Genetics, Dept. of Genetics, University of Sheffield, 1991

Previous Positions

·         Senior Research Fellow, Leukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton. (Sep 2001 – Dec 2007)

·         Research Assistant, LRF Centre for Clinical Epidemiology, University of Leeds (Mar - Aug 2001)

·         PhD Student, LRF Centre for Clinical Epidemiology, University of Leeds (Mar 1998 - Feb 2001)

·         Research Assistant / Data Manager, LRF UK Cancer Cytogenetics Group Karyotype Database, Dept. of Haematology, Royal Free Hospital, London (Jun 1992 - Feb 1998)

Memberships

·         Member of NCRI Childhood Cancer and Leukaemia Group (CCLG) Leukaemia Subgroup (February  2011 onwards)

·         International Membership of the American Society of Hematology (Apr 2007 onwards)

·         NCRI Haematological Malgnancies Study Group - Adult ALL Working Party (Feb 2005 onwards)

·         Leukaemia Research Fund (LRF) / Childhood Leukaemia Working Party (CLWP) Childhood Leukaemia Cell Bank Steering Committee (Jan 2004 onwards)

·         NHS Southampton & SW Hampshire Local Research Ethics Committee (Jun 2003 - Sept 2005)

 

Research Interests

My principal research interest is the integration of genetic markers into traditional epidemiological studies and clinical trials. I think that the genetic classification of tumours can help us to understand the differential response of individuals to environmental exposures and therapy. My current research revolves around incorporating high-quality cytogenetic data into clinical trials in order to explore the prognostic significance of chromosomal abnormalities in acute leukaemia. Over the past five years I have been analysing cytogenetic, clinical and survival data derived from two major national trials of childhood and adult acute lymphoblastic leukaemia. In addition, I have been involved in collecting, classifying and analysing cytogenetic data for several national trials of acute myeloid leukaemia and an international trial of infant acute lymphoblastic leukaemia. Previously, my research has included analysing a case-control study of adult acute myeloid leukaemia which incorporated cytogenetic data. Using this cytogenetic data I was able to explore the risk of developing different sub-types of acute myeloid leukaemia in relation to a traditional exposure (smoking) and genetic predisposition (metabolic polymorphisms).

Funding

Leukaemia Research Cytogenetics Group Specialist Programme (CJ Harrison, AV Moorman) Leukaemia & Lymphoma Research, £1,937,659 for 5 years effective from 1 April 2011.

Prognostic relevance of chromosomal abnormalities in acute leukaemia (AV Moorman, CJ Harrison) Leukaemia Research Fund, Sept 2007-2010 (£94,791.38)

Gene fusion involving the short arm of chromosome 9 and their association with clinical outcome in patients with acute lymphoblastic leukaemia (ALL) (JC Strefford, AV Moorman, G Packham, CJ Harrison) Leukaemia Research Fund, Jul 2006-2008 (£106,590)

Development of a Cytogenetic Information Management System (CIMS) for the LRF UKCCG Karyotype Database in Acute Leukaemia and the LRF UK Myeloma Forum Cytogenetics Database (AV Moorman, CJ Harrison, FM Ross) Leukaemia Research Fund, Sept 2005-2008 (£99,824)

Molecular determinants of response and resistance to Imatinib Mesylate when used in combination with standard chemotherapy in childhood Ph+ ALL (V Saha, AV Moorman, JAE Irving, NJ Goulden, J Kaeda, AG Hall) Leukaemia Research Fund, Apr 2004-2008 (£174,500)

Automation to Facilitate Interphase FISH Screening for Significant Chromosomal Abnormalities in Acute Lymphoblastic Leukaemia (CJ Harrison, AV Moorman) Leukaemia Research Fund, Jul 2003-2006 (£125,277)